After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
ORGO belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Organogenesis Holdings Inc is $564.39M. A total of 1.38 million shares were traded on the day, compared to an average of 2.00M shares.
In the most recent transaction, Driscoll Michael Joseph bought 25,000 shares of ORGO for 5.08 per share on Mar 04 ’25. In a previous transaction on Mar 04 ’25, Driscoll Michael Joseph sold 25,000 shares at 5.10 per share. ORGO shares that Director owns now total 166,879.
Among the insiders who sold shares, Gillheeney Gary S. disposed of 55,615 shares on Dec 13 ’24 at a per-share price of $3.36. This resulted in the President and CEO holding 3,044,779 shares of ORGO after the transaction. In another insider transaction, Gillheeney Gary S. sold 5,585 shares at $3.49 per share on Dec 16 ’24. Company shares held by the President and CEO now total 3,039,194.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ORGO has a high of $6.71 and a low of $2.16.
As of this writing, ORGO has an earnings estimate of -$0.03 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of -$0.03 per share and a lower estimate of -$0.03.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ORGO’s latest balance sheet shows that the firm has $113.93M in Cash & Short Term Investments as of fiscal 2021. There were $132.30M in debt and $82.70M in liabilities at the time. Its Book Value Per Share was $2.09, while its Total Shareholder’s Equity was $241.34M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ORGO is Buy with a score of 4.50.
